UNSPSC 51351632: Estrone hydrogen sulfate

This classification denotes an estrogen with the molecular formula C18H22O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QTL48N278K, chemically known as estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, but more generally known as estrone hydrogen sulfate, which bears US NIH Compound Identifier 699. European Medicines Agency schedules estrone hydrogen sulfate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07251MIG.

Most nations, for tariff purposes, schedule estrone hydrogen sulfate under HS 29372300. SMILES: C[C@]12CC[C@@H]3C4CCC(CC4CC[C@H]3[C@@H]1CCC2=O)OS(=O)(=O)O.

UNSPSC 51351632 Estrone hydrogen sulfate is a Commodity code capturing pharmaceutical products — specifically hormone-based pharmaceuticals and related compounds — that state and local governments procure through cooperative purchasing arrangements and direct supply agreements with authorized wholesalers. State and local issuers soliciting under this code include multistate cooperative purchasing alliances, state procurement offices, and participating health and social-service agencies. The work involves establishing supply contracts for generic and brand pharmaceutical products distributed through three-tier supply chains: manufacturers or authorized resellers provide products to approved wholesalers, which then deliver to participating public facilities including state agencies, county health departments, and local government operations. Vendors must comply with current Good Manufacturing Practices, the Drug Supply Chain Security Act, FDA requirements, and maintain contractual relationships with specified wholesalers including chargeback systems.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products serving participating state and local government facilities across Minnesota and Oregon, with proposals due March 26, 2026. The procurement requires vendors to supply products through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, with awarded vendors effective July 1, 2026 and a two-year initial contract term. Evaluation is weighted heavily on price competitiveness (75 percent), with secondary emphasis on fixed pricing, EDI capability, administrative fee compliance, and format requirements. Vendors must carry $5 million in commercial general liability insurance, $2 million in network security and privacy liability, and $2 million in professional liability, and are subject to performance penalties ranging from $200 to $1,500 per violation for late reporting or missed onboarding timelines.